General Anesthesia Drugs: Moving Beyond Traditional Anesthetic Techniques
Advances in technologies and assays have been opening new avenues in drug discovery, creating opportunities to study complex disease mechanisms and find cures for the indications. As numerous developments were brought to drug discovery process as well as surgical interventions, the importance of general anesthesia drugs has moved from merely putting patients to sleep in operating rooms to delivering best possible pre-, intra-, and postoperative care to meet the needs of patients undergoing major surgery. Over the years, from ether to Propofol, newer range of anesthetic drugs with fewer side effects came in to use in a number of operational procedures. Moreover, technological changes in anesthesiology and its practice including ‘robotic’ anesthesia and ‘tele’ anesthesia have been offering the possibility of distant preoperative assessment of the patient’s fitness for specific anesthesia drug and the control of its delivery.
While highly specific and target oriented technologies have reduced the anesthesia-associated mortality and morbidity, advances in cell biology, genetics, and molecular biology have spurred the development of better anesthetic drugs with minimal or no complication. An increase in global volume of surgical activities as a result of aging population growth and high prevalence of cardiovascular diseases has worked in tandem with rising demand for general anesthesia drugs.
General Anaesthesia Drugs Market - Key Research Findings
- The global general anaesthesia drugs market size in 2018 was ~US$ 4.2 Bn.
- The general anaesthesia drugs market is expected to grow at a CAGR of ~3% during the forecast period of 2019-2029.
- General anaesthesia drugs are widely used in several surgeries, and increase in the number of cardiovascular and other diseases is expected to fuel the growth of the general anaesthesia drugs market. Moreover, the availability of technologically advanced drug delivery devices and the development of specific targeted drugs is likely to foster the growth of the general anaesthesia drugs market. In addition, the proliferating general anaesthesia drugs portfolio and the number of clinical trials for the development of general anaesthesia drugs with respect to specific indications is expected to foster substantial revenue generation in the general anaesthesia drugs market.
- Collectively, North America and Europe are likely to contribute a significant share in the general anaesthesia drugs market by the end of 2029.
- North America continues to be a prominent regional market for general anaesthesia drugs manufacturers owing to an increase in the adoption of novel therapeutics as well as the launch of new general anaesthesia drugs into the market.
- Europe has also witnessed significant growth in the general anaesthesia drugs market owing to an increasing number of surgeries and the rising demand for the latest technologies and healthcare facilities.
- East Asia is likely to witness growth in the general anaesthesia drugs market due to increasing disposable income and the emergence of several cost-effective generic drugs.
- Propofol is expected to remain a prominent drug class segment in the general anaesthesia drugs market.
- Due to its lipophilic nature and rapid onset of action with minimal side effects, the general anaesthesia drug Propofol is highly preferred for surgeries.
Key Factors Shaping the General Anaesthesia Drugs Market
- Increasing Demographic Trends in the Geriatric Population to Boost the General Anaesthesia Drugs Market
People aged 65 years and above are more prone to chronic diseases, due to which they are likely to require a larger number of procedures. According to a Population Reference Bureau report in 2016, the number of Americans aged 65 and above is projected to be 98 million by 2060, and the group share of the elderly population from the total population is estimated to be nearly 24%. Moreover, the increasing burden of cardiovascular diseases that require surgeries is fuelling the growth of the general anaesthesia drugs market. In addition, the increasing frequency of co-morbidities among the aging population increases the risk of toxicities and surgical complications related with general anaesthetics. The rising population and increase in the number of procedures that require anaesthesia are some of the factors that are likely to spur the growth of the general anaesthesia drugs market.
- Rising Utilization of Anaesthesia Drugs for Outpatient Procedures to Contribute Significantly to the Growth of the General Anaesthesia Drugs Market
Ambulatory anaesthesia provides rapid recovery from general anaesthesia drugs, which leads to the early discharge of patients and, at the same time, provides several benefits to healthcare providers, patients, as well as third-party payers and hospitals. The number of ambulatory surgeries has been increasing at an alarming rate due to continuous improvements in general anaesthesia drugs & related techniques, and the easy availability of short-acting anaesthetics with minimal side effects. Moreover, appropriate discharge criteria and the availability of minimal invasive surgical techniques has led to an increase in the adoption of ambulatory surgeries. Furthermore, an increasing number of minimally invasive diagnostic and surgical procedures that are performed on an outpatient basis require a large number of general anaesthesia drugs. General anaesthesia drugs have the potential to impact on the efficacy as well as the cost of care in these outpatient settings. Thus, the general anaesthesia drugs market is estimated to register significant growth due to an increase in the number of surgeries performed in outpatient settings.
- Rising Launch of New Anaesthetic Drugs Expected to Propel the Growth of the General Anaesthesia Drugs Market
Manufacturers are focusing on the launch of new anaesthetic drugs. For instance, Vétoquinol, in collaboration with Jurox Pty. Ltd., will soon launch a new injectable anaesthetic. Manufacturers are also engaged in entering into various collaboration and licensing agreements to ensure the global availability of their products. Collaboration partners seek regulatory approval for the launch and commercialisation of their products in different geographies. For instance, in September 2017, AstraZeneca and Aspen announced that they have entered into an agreement for the remaining rights to anaesthetics medicines. Moreover, various manufacturers aim at expanding and accelerating their pipeline drugs portfolio for the launch of new general anaesthesia drugs into the market. For instance, Paion UK Ltd.’s lead candidate, Remimazolam (CNS7056), which is an intravenous general anaesthesia drugs, has submitted an NDA filing in 2018. Thus, rising research and development and the launch of new drugs is expected to significantly drive the general anaesthetic drugs market.
Surgical Complexities and Patient Safety Expectations to Drive New Developments
The migration of health care systems from ‘fee-for-service (FFS)’ to ‘pay-for-performance (P4P)’ models have been forcing the healthcare professionals to reevaluate how they approach the delivery of care. Over the years, a large number of intravenous and inhalation agents of general anesthesia drugs have been introduced, and in parallel various drugs have undergone clinical usage and then withdrawn when found unreliable. The development of safer drugs were propelled by increasing surgical complexity and severity of patient illness along with growing expectations of patient safety. As general anesthesia drugs are commonly associated with several side effects, manufacturers are directing their investments towards the development of new formulations of existing agents or entirely new chemical entities in strides to improve safety, efficacy, recovery profile, and minimize side effects.
Considering the nature of the product, manufacturers are constantly focusing on keeping up with several regulations and guidelines on general anesthesia drugs which have been revised and updated to improve procedural safety and efficacy. Although the robotic or minimally invasive surgeries have significantly transformed the operational procedures, these processes can take longer than open surgery which may increase the possible risks of anesthesia, thereby compelling manufacturers to innovate their products with reduced side effects.
The U.S. Takes the Center Stage
Despite many advancements in anesthesia techniques and availability of newer and safer drugs, much more scientific exploration and large clinical trials are needed to provide the greatest level of evidence and safety, prior to widespread clinical implementation. Growth prospects of the general anesthesia drugs market are relatively high in the U.S., driven by increasing risk of organ failures and cardiac diseases among baby boomers along with significant restructuring of the healthcare system in the country. Rapid adoption of innovative business models focused on novel strategies such as seeking faster approval of drugs for reduced time-to-market and more reliance on external partners, academia, and industry consortia will continue to favor the manufacturers operating in the nation.
Tracking the Lasting Effects of General Anesthesia Drugs on Human Health
Although the introduction of general anesthesia drugs dates back to 1840s, they continue to associate with several side effects including elevation in blood pressure and heart rate, respiratory depression, amnesia, and even hallucinations. For example, opioid-containing anesthesia has been linked with post-surgery nausea, vomiting, and drowsiness that can hinder the patient’s recovery. A focus on opioid-free general anesthesia, aligning with clinical strategies that include the use of multimodal analgesia and enhanced recovery after surgery (ERAS) initiatives, has been making a headway in reducing the use of addictive medications prior to surgical interventions.
Modern general anesthesia drugs have not only enabled complex surgical procedures to be performed safely on patients but also has significantly advanced human medicine. However, several studies regarding the impact of general anesthesia drugs on human health are still underway. The jury is still out as a new Israeli study links child born via C-section under general anesthesia with the risk of developing autism, while another study claims that general anesthesia in infancy has no detectable impact on brain development.
Propofol remains the top-selling category
Sevoflurane to witness high adoption
Intravenous administration remains highly preferred
Administration through inhalation gains momentum
Hospitals remain the top end user
Use in ambulatory surgical centers grows rapidly
How Growth will Unfold
While various clinical trials are underway to unfold the possible impacts of general anesthesia drugs on both adult and pediatric health, manufacturers are largely engaged in entering into strategic collaboration with research institutes for the development of innovative solutions. As the developing and aging brain may be vulnerable to general anesthesia drugs, manufacturers are directing towards the development of drugs and routes of administration with faster and predictable effects with easy reversibility of action and lesser side effects profiles. Further, leveraging advancements in novel drug delivery systems and monitoring equipment making anesthetic practice faster, simpler, and safer will remain a key focus area of the market players.
* This data is only a representation. Actual data may vary and will be available in report.
Click Here To Know How The Growth Will UnfoldCustom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Overview
General Anesthesia Drugs Market Analysis 2019 - 2029
A recent market study published by FMI on the general anesthesia drugs market during 2014-2018 & forecast for 2019-2029 offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the general anesthesia drugs market, the growth prospects of the market have been obtained with maximum precision.
General Anesthesia Drugs Market Taxonomy
The global general anesthesia drugs market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
By Drug Class
- Propofol
- Sevoflurane
- Dexmedetomidine
- Desflurane
- Remifentanil
- Midazolam
- Others
- (Others – Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental etc.)
By Route of Administration
- Intravenous Anesthesia
- Inhaled Anesthesia
By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
What's Included
The report commences with the executive summary of the general anesthesia drugs market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the general anesthesia drugs market.
Readers can find the detailed taxonomy and the definition of the general anesthesia drugs market in this chapter, which will help them understand the basic information about the general anesthesia drugs market.
The report provides key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with key market developments and product innovations.
This section explain the global market value analysis and forecast for the general anesthesia drugs market between the forecast periods of 2014-2029. This chapter includes the detailed analysis of the historical general anesthesia drugs market, along with an opportunity analysis of the future. Readers can also find the absolute opportunity for the current year (2019 – 2020), and an incremental opportunity for the forecast period (2019 – 2029).
This chapter explains the key macro-economic factors that are expected to influence the growth of the general anesthesia drugs market over the forecast period. Along with macro-economic factors, this section also highlights the opportunity analysis for the general anesthesia drugs market. Moreover, this chapter highlights the key market dynamics of the general anesthesia drugs market, which include the drivers, restraints, and trends. Readers can also find the key success factors in the general anesthesia drugs market.
Based on drug class, the general anesthesia drugs market is segmented into Propofol, Sevoflurane, Dexmedetomidine, Desflurane, Remifentanil, Midazolam and others such as Sufentanil, Fentanyl, Ketamine, Isoflurane, Thiopental, etc. In this chapter, readers can find information about the year-on-year growth in the general anesthesia drugs market and market attractiveness analysis based on the drug class.
Based on the route of administration, the general anesthesia drugs market is segmented as intravenous anesthesia and inhaled anesthesia. In this chapter, readers can find information about the year on year growth in the general anesthesia drugs market and market attractiveness analysis based on the route of administration.
This chapter provides details about the general anesthesia drugs market on the basis of end user, and has been classified into hospitals, specialty clinics, and ambulatory surgical centers. In this chapter, readers can understand the market attractive analysis based on the end user.
This chapter explains how the general anesthesia drugs market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
This chapter includes a detailed analysis of the growth of the North America general anesthesia drugs market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the impact analysis of the drivers and restraints of the general anesthesia drugs market in North America.
Readers can find detailed information about the regional trends, which are impacting the growth of the Latin America general anesthesia drugs market. This chapter also includes the growth prospects of the general anesthesia drugs market in the leading LATAM countries such as Brazil, Mexico, Argentina, and the Rest of Latin America.
Important growth prospects of the general anesthesia drugs market based on its distribution channel in several countries, such as Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe, are included in this chapter.
India, Indonesia, Thailand, and Malaysia are the leading countries in the South Asia region, which are the prime subjects of assessment to obtain the growth prospects of the South Asia general anesthesia drugs market in this chapter. Readers can find detailed information about the growth parameters of the South Asia general anesthesia drugs market during the period 2019-2029.
This chapter highlights the growth of the general anesthesia drugs market in East Asia by focusing on China, Japan, and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the general anesthesia drugs market in East Asia.
In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania general anesthesia drugs market.
This chapter provides information about how the general anesthesia drugs market will grow in the major countries in the MEA region, such as GCC Countries, South Africa, Turkey, and the rest of MEA, during the forecast period 2019 - 2029.
This chapter provides information about how the general anesthesia drugs market will grow in Brazil during the forecast period 2019 - 2029.
This chapter highlights the growth of the general anesthesia drugs market in China during the forecast period 2019 - 2029.
This chapter includes a detailed analysis of the growth of the India general anesthesia drugs market during the forecast period 2019 - 2029.
This chapter includes the following forecast factors:
Increasing number of surgeries
New anesthesia drug approvals
R&D investment by major players
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the general anesthesia drugs report.
This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the general anesthesia drugs market.
How the research was conducted?
Primary Research
- C - Level Executives
- Marketing Directors
- Sales Heads
- Portfolio Managers
- Purchasing Managers
- Medical Officers
- Strategy Advisors
- R&D Managers
- Product Manufacturers
- Distributors
- Pharmacists / Pharmacy Benefit Managers
- Hospital Purchasing Departments
- Physicians / Nursing Managers
- Industry Experts
- Current Market Dynamics and Challenges
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Disease Patterns, Treatment and Prescription Patterns
- Regulatory and Reimbursement Landscape
- Products in Pipeline and Clinical Development
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
Secondary Research
- Industry Magazines
- Association of Anesthetists
- American Society of Anesthesiologists
- Company Press Releases
- Annual Reports and Investor Presentations
- Peer-reviewed Journals
- Government Websites and Publications
- Trade Websites
- Clinical Trial Registries
- Country-specific Regulatory Authorities
- World Bank, WHO
Primary Interview Splits
To Learn More About our Comprehensive Perspective on General Anesthesia Drugs Market,
Get in touch
COVID -19 : Impact Analysis
Request the coronavirus impact analysis across industries and markets
Request Covid -19 ImpactOur Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.